Weight Loss & MetabolicStrong Evidence

Cagrilintide + Semaglutide Peptide Therapy

Benefits, Side Effects, Cost & Protocols

CagriSema is a combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) being developed by Novo Nordisk. The dual mechanism targets both amylin and GLP-1 pathways for potentially greater weight loss than either agent alone.

ByChris Riley(CFA)&Alex Evans, PharmD, MBA(PharmD, MBA)|Updated June 8, 2026

Clinically Reviewed

Reviewed by Alex Evans, PharmD, MBA · Updated June 2026

Evidence-Based

Sourced from FDA, PubMed & ClinicalTrials.gov · View sources

FDA Status

Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.

Evidence

Strong Evidence

Who Is Cagrilintide + Semaglutide Best For?

Enhanced weight managementDual mechanism approachAppetite control

How Cagrilintide + Semaglutide Works

Combines amylin-mediated satiety and gastric effects with GLP-1 receptor activation for dual metabolic pathway targeting.

Cagrilintide + Semaglutide FAQ

What is CAGRILINTIDE + SEMAGLUTIDE?

A dual-action combination of Cagrilintide (amylin analog) and Semaglutide (GLP-1 agonist) being researched for enhanced weight management effects through complementary mechanisms.

How does CAGRILINTIDE + SEMAGLUTIDE work?

Combines amylin-mediated satiety and gastric effects with GLP-1 receptor activation for dual metabolic pathway targeting.

Is CAGRILINTIDE + SEMAGLUTIDE legal to buy?

CAGRILINTIDE + SEMAGLUTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.

Where can I buy CAGRILINTIDE + SEMAGLUTIDE?

CAGRILINTIDE + SEMAGLUTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.

What category does CAGRILINTIDE + SEMAGLUTIDE belong to?

CAGRILINTIDE + SEMAGLUTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.

What are the research benefits of CAGRILINTIDE + SEMAGLUTIDE?

CAGRILINTIDE + SEMAGLUTIDE has been studied for: Enhanced weight management, Dual mechanism approach, Appetite control. Dual-action blend targeting multiple metabolic pathways.

Key Studies

60 total on PubMed0

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

Garvey WT, Blüher M, Osorto Contreras CK et al

N Engl J MedPhase 3

Cagrilintide-semaglutide reduced body weight by 20.4% vs 3.0% with placebo.

Cagrilintide-semaglutide reduced body weight by 20.4% vs 3.0% with placebo

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Davies MJ, Bajaj HS, Broholm C et al

N Engl J MedPhase 3

Cagrilintide-semaglutide reduced body weight by 13.7% vs 3.4% with placebo in type 2 diabetes.

Cagrilintide-semaglutide reduced body weight by 13.7% vs 3.4% with placebo in type 2 diabetes

Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials

El-Sheikh M, Sillassen CDB, Wisborg FD et al

BMJ Open

Protocol for systematic review of cardiovascular effects of incretin-based drugs in heart failure patients

Incretin-based therapies for the treatment of obesity-related diseases

Cagrilintide + Semaglutide News

Significant body weight reduction with cagrilintide-semaglutide therapy - 2 Minute Medicine

2 Minute Medicine · 9 months ago

CagriSema Superior to Semaglutide for HbA1c, Weight Loss in Type 2 Diabetes - Endocrinology Advisor

Endocrinology Advisor · 4 months ago

Weight loss: New drug CagriSema leads to 14% weight loss in trial - Medical News Today

Medical News Today · 3 months ago

Can amylin weight-loss drugs compete in a world of GLP-1s? - Chemical & Engineering News

Chemical & Engineering News · 1 month ago

Cagrilintide Demonstrates Promising Results as Monotherapy for Obesity Management - Pharmacy Times

Pharmacy Times · 8 months ago

News aggregated via Google News. Inclusion does not imply endorsement.

Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptide therapies have not been evaluated by the FDA for most listed indications.All prices shown are estimates based on publicly available data and may not reflect current pricing — providers and brands set their own prices and can change them at any time. Always verify pricing directly with the provider before purchasing. Consult a licensed healthcare provider before starting any peptide protocol.

Ready to explore Cagrilintide + Semaglutide with a provider?

Take our 2-minute quiz to get matched with a board-certified provider specializing in Cagrilintide + Semaglutide.

Take the Quiz →